Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoleucine SCHEMBL112017 | 1.00 | DPP4 (0.43) | DPP4DPP8DPP9DPP7SLC7A5 | |
| Isoleucine SCHEMBL6872156 | 0.93 | DPP4 (0.39) | DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL6872155 | 0.93 | DPP4 (0.39) | DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL6872158 | 0.93 | DPP4 (0.39) | DPP4DPP8DPP9DPP7 | |
| Isoleucine SCHEMBL391313 | 0.85 | DPP4 (0.70) | DPP4DPP8DPP9DPP7 | |
| Valine SCHEMBL5604912 | 0.83 | SLC7A5 (0.54) | DPP4DPP8DPP7SLC7A5 | |
| Isoleucine SCHEMBL4468657 | 0.78 | DPP4 (0.42) | DPP4DPP8DPP9DPP7SLC7A5 | |
| Isoleucine SCHEMBL6428278 | 0.78 | DPP4 (0.42) | DPP4DPP8DPP9DPP7SLC7A5 | |
| Isoleucine SCHEMBL4468654 | 0.78 | DPP4 (0.42) | DPP4DPP8DPP9DPP7SLC7A5 | |
| Isoleucine SCHEMBL20340795 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100429201-C | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2008-10-29 | — | — | CN | claimed |
| CN-116600803-A | Macrocyclic urea orexin receptor agonists | 默沙东有限责任公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116249697-A | Bicycloheptane pyrrolidine orexin receptor agonists | 默沙东有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-109642908-B | Compounds useful for treating metabolic disorders | 哈佛学院院长及董事 | 2022-08-16 | — | — | CN | disclosed |
| CN-113388007-A | Ultra-pure agonists of guanylate cyclase C, methods of making and using the same | 博士医疗爱尔兰有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-113302189-A | Inhibitors of alpha-amino-beta-carboxyadipimic acid semialdehyde decarboxylating enzyme | TES制药有限责任公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-113121450-A | Alpha-amino-beta-carboxymuconate semialdehyde decarboxylase inhibitors | TES制药有限责任公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-105764916-B | Ultra-pure agonists of guanylate cyclase C, methods of making and using the same | 博士医疗爱尔兰有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-107207483-B | Alpha-amino-beta-carboxymuconate semialdehyde decarboxylase inhibitors | TES制药有限责任公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-105963676-B | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2020-02-18 | — | — | CN | disclosed |
| CN-1700911-A | Combination drug | EISAI CO LTD (JP) | 2005-11-23 | — | — | CN | disclosed |
| CN-1636593-A | Novel effectors of dipeptidyl peptidase IV | PROSIDION LTD (GB) | 2005-07-13 | — | — | CN | disclosed |
| CN-1637018-A | Novel effectors of dipeptidyl peptidase IV | PROSIDION LTD (GB) | 2005-07-13 | — | — | CN | disclosed |
| CN-1633420-A | Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors | TORRENT PHARMACEUTICALS LTD (IN) | 2005-06-29 | — | — | CN | disclosed |
| CN-1443068-A | Combinations of depepotidyl peptidase IV inhibitors and other antidiabetic agents for treatment of diabete mellitus | SMITHKLINE BEECHAM PLC (GB) | 2003-09-17 | — | — | CN | disclosed |
| EP-1328271-A2 | METHOD FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHOLOGICAL DISORDERS | Probiodrug AG (DE) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002034243-A2 | METHOD FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHOLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2002-05-02 | — | — | WO | disclosed |
| CN-1343924-A | Chinese-character 'first pyhonetic letter table-shape code' encode method and its keyboard | QIN RONGFU (CN) | 2002-04-10 | — | — | CN | disclosed |
| CN-1303381-A | Novel effectors of dipeptidyl peptidase IV | PROBIODRUG GES FUER ARZNEIM (DE) | 2001-07-11 | — | — | CN | disclosed |
| CN-1283108-A | Chlamydia protein, gene sequence and use thereof | ANTEX BIOLOFICS INC (US) | 2001-02-07 | — | — | CN | disclosed |